Get the Stockscreener App
21.15
7.85%
1.54
Travere Therapeutics Inc stock is traded at $21.15, with a volume of 3.96M.
It is up +7.85% in the last 24 hours and up +32.52% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$19.61
Open:
$19.71
24h Volume:
3.96M
Relative Volume:
2.55
Market Cap:
$1.89B
Revenue:
$333.87M
Net Income/Loss:
$-169.00M
P/E Ratio:
-10.37
EPS:
-2.04
Net Cash Flow:
$-157.30M
1W Performance:
+19.49%
1M Performance:
+32.52%
6M Performance:
+7.36%
1Y Performance:
+110.45%
1-Day Range:
$19.46
$21.22
1-Week Range:
$17.27
$21.22
52-Week Range:
$9.435
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
21.15 | 1.62B | 333.87M | -169.00M | -157.30M | -2.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
Transcript : Travere Therapeutics, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-04-2025 02 - MarketScreener
Travere Therapeutics Inc. stock trend forecastJuly 2025 Pullbacks & Weekly High Return Opportunities - Newser
Travere Therapeutics at Cantor Conference: Strategic Insights on FILSPARI By Investing.com - Investing.com Canada
Travere Therapeutics Inc. recovery potential after sell off2025 Big Picture & High Win Rate Trade Alerts - Newser
What is the earnings history of Travere Therapeutics Inc.Price Action & Verified Momentum Watchlists - khodrobank.com
Travere Therapeutics, Inc.'s (NASDAQ:TVTX) Price Is Right But Growth Is Lacking - 富途牛牛
Why Travere Therapeutics Inc. is moving todayWeekly Trade Recap & Daily Profit Maximizing Trade Tips - Newser
Will Travere Therapeutics Inc. continue its uptrendQuarterly Risk Review & High Win Rate Trade Alerts - Newser
Travere Therapeutics Inc. stock prediction for this weekPortfolio Growth Summary & Community Supported Trade Ideas - Newser
Is Travere Therapeutics Inc.’s growth already priced inExit Point & AI Forecast for Swing Trade Picks - khodrobank.com
Will Travere Therapeutics Inc. outperform small cap indexes2025 Geopolitical Influence & Safe Entry Zone Identification - khodrobank.com
How to interpret RSI for Travere Therapeutics Inc. stockMarket Trend Review & AI Driven Stock Reports - Newser
Travere Therapeutics shares rise 4.74% intraday after presenting positive long-term data for pegtibatinase at the International Congress of Inborn Errors of Metabolism. - AInvest
Can Travere Therapeutics Inc. be the next market leaderWeekly Trade Analysis & Capital Efficient Trade Techniques - khodrobank.com
Travere Therapeutics Presents Abstracts at the 15th International Congress of Inborn Errors of Metabolism - Business Wire
Should you hold or exit Travere Therapeutics Inc. now2025 Market Trends & Growth Focused Stock Pick Reports - Newser
Chart based analysis of Travere Therapeutics Inc. trendsJuly 2025 Price Swings & Accurate Trade Setup Notifications - Newser
Technical analysis overview for Travere Therapeutics Inc. stockEarnings Performance Report & Free Low Drawdown Momentum Trade Ideas - Newser
Is Travere Therapeutics Inc. stock ready for a breakoutJuly 2025 Review & Expert Approved Momentum Ideas - Newser
Is Travere Therapeutics Inc. trending in predictive chart modelsInsider Buying & Verified Entry Point Detection - Newser
Earnings visualization tools for Travere Therapeutics Inc.2025 Stock Rankings & Expert Approved Momentum Ideas - Newser
Statistical indicators supporting Travere Therapeutics Inc.’s strength2025 Buyback Activity & Target Return Focused Picks - Newser
Travere Therapeutics: Strategic Positioning in Renal Disease with Near-Term Catalysts and Valuation Potential - AInvest
Nephrotic Syndrome Pipeline Analysis, 2025 by DelveInsight | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squibb, ChemoCentryx, SynAct Pharm - Barchart.com
Transcript : Travere Therapeutics, Inc. Presents at Citi's Biopharma Back to School Conference, Sep-02-2025 03 - MarketScreener
Can Travere Therapeutics Inc. rally from current levels2025 Investor Takeaways & Verified Trade Idea Suggestions - Newser
Benchmark Reaffirms Buy Rating on Ligand with Raised PT to $175. - AInvest
What is Travere Therapeutics Inc.’s book value per shareTrade Analysis Report & Daily Oversold Stock Bounce Ideas - khodrobank.com
Risk vs reward if holding onto Travere Therapeutics Inc.Trend Reversal & Consistent Growth Stock Picks - Newser
Is Travere Therapeutics Inc. reversing from oversold territoryJuly 2025 Opening Moves & Consistent Profit Trade Alerts - Newser
Aug Levels: What is Travere Therapeutics Inc.’s book value per shareJuly 2025 Intraday Action & Community Consensus Trade Signals - khodrobank.com
Is now the right time to enter Travere Therapeutics Inc.July 2025 Spike Watch & Detailed Earnings Play Alerts - khodrobank.com
How to monitor Travere Therapeutics Inc. with trend dashboardsChart Signals & High Accuracy Swing Trade Signals - Newser
Pullback Watch: Does Travere Therapeutics Inc. have pricing powerJuly 2025 Weekly Recap & Risk Controlled Swing Alerts - khodrobank.com
Using data filters to optimize entry into Travere Therapeutics Inc.Forecast Cut & High Accuracy Trade Alerts - Newser
Why Travere Therapeutics Inc. stock attracts strong analyst attentionJuly 2025 Levels & Weekly High Return Opportunities - Newser
Tick level data insight on Travere Therapeutics Inc. volatilityDividend Hike & Free High Return Stock Watch Alerts - Newser
Identifying reversal signals in Travere Therapeutics Inc.2025 Price Momentum & Reliable Trade Execution Plans - Newser
Multi asset correlation models including Travere Therapeutics Inc.Quarterly Profit Report & AI Powered Market Trend Analysis - Newser
Price action breakdown for Travere Therapeutics Inc.2025 Earnings Impact & Real-Time Volume Analysis Alerts - Newser
Visualizing Travere Therapeutics Inc. stock with heatmapsQuarterly Performance Summary & Risk Adjusted Swing Trade Ideas - Newser
Travere Therapeutics Inc. Attempts Reversal From Key Support getLinesFromResByArray error: size == 0 - classian.co.kr
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Travere Therapeutics Inc Stock (TVTX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Inrig Jula | CHIEF MEDICAL OFFICER |
Jul 01 '25 |
Sale |
14.65 |
815 |
11,940 |
88,787 |
| Cline Christopher R. | CHIEF FINANCIAL OFFICER |
May 05 '25 |
Sale |
21.05 |
1,784 |
37,553 |
93,126 |
| Dube Eric M | CHIEF EXECUTIVE OFFICER |
May 05 '25 |
Sale |
21.05 |
18,924 |
398,350 |
419,173 |
| Heerma Peter | CHIEF COMMERCIAL OFFICER |
May 05 '25 |
Sale |
21.05 |
1,771 |
37,280 |
128,215 |
| ROTE WILLIAM E. | Chief Research Officer |
May 05 '25 |
Sale |
21.05 |
3,198 |
67,318 |
100,241 |
| REED ELIZABETH E | Chief Legal Officer and GC |
May 05 '25 |
Sale |
21.05 |
4,920 |
103,566 |
89,482 |
1.75%
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):